Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity
Authors:
- 1 January 2016
- journal article
- case report
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 63 (1.2) , 149-151
Abstract
Afatinib could be a well-tolerated EGFR-TKI that could be chosen for its relatively low hepatotoxicity, which is attributable to its having a different metabolic mechanism compared to other EGFR-TKIs.Keywords
This publication has 6 references indexed in Scilit:
- Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3Cancer Science, 2015
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Polymorphisms of CYP2D6 Gene and Gefitinib-Induced HepatotoxicityClinical Lung Cancer, 2013
- Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteersCancer Chemotherapy and Pharmacology, 2011
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialThe Lancet Oncology, 2010
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2006